News of mega-mergers involving the likes of Pfizer and Wyeth or Merck and Schering Plough have turned the pharmaceutical industry on its ear. But what does this mean for you and your patients? John Kreger, a principal with the health care investment bank William Blair & Company, tells the Chicago Tribune's Bruce Japsen about how consolidation among drug companies could impact doctors and their patients.
When Drug Companies Merge & the Effect on Your Practice

Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
News of mega-mergers involving the likes of Pfizer and Wyeth or Merck and Schering Plough have turned the pharmaceutical industry on its ear. But what does this mean for you and your patients? John Kreger, a principal with the health care investment bank William Blair & Company, tells the Chicago Tribune's Bruce Japsen about how consolidation among drug companies could impact doctors and their patients.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Phase 3 study results of plozasiran in patients with FCS
Evolutions in Duchenne Muscular Dystrophy: Treatment Implications for the Present and Future
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
Clinical Practice Guidelines for Hyperlipidemia: What Are the Recommendations?
Personalizing Care Within the RCC Treatment Paradigm
Navigating Myasthenia Gravis in Adolescents and Young Adults
Analysis of Patients With and Without AF Living With HFmrEF/HFpEF: FINEARTS-HF
Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?